Acadian Asset Management LLC cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 703,747 shares of the medical research company’s stock after selling 44,269 shares during the quarter. Bio-Rad Laboratories accounts for 0.9% of Acadian Asset Management LLC’s portfolio, making the stock its 25th largest position. Acadian Asset Management LLC owned about 2.36% of Bio-Rad Laboratories worth $220,268,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently bought and sold shares of the business. Boussard & Gavaudan Investment Management LLP acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $202,000. Raymond James Trust N.A. acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at about $212,000. World Asset Management Inc acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at about $213,000. We Are One Seven LLC acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $254,000. Finally, Atria Investments LLC acquired a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $337,000. 63.26% of the stock is owned by institutional investors.
A number of equities analysts have recently weighed in on the company. Barclays assumed coverage on Bio-Rad Laboratories in a report on Wednesday, September 5th. They issued an “equal weight” rating and a $345.00 target price on the stock. Goldman Sachs Group assumed coverage on Bio-Rad Laboratories in a report on Wednesday, October 17th. They issued a “buy” rating and a $350.00 target price on the stock. Zacks Investment Research downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Jefferies Financial Group upped their target price on Bio-Rad Laboratories from $325.00 to $355.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Finally, Morgan Stanley assumed coverage on Bio-Rad Laboratories in a report on Thursday, September 20th. They issued an “equal weight” rating and a $335.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Bio-Rad Laboratories has an average rating of “Buy” and a consensus price target of $342.71.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Tuesday, August 7th. The medical research company reported $1.64 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.37. Bio-Rad Laboratories had a return on equity of 4.23% and a net margin of 44.77%. The firm had revenue of $575.91 million for the quarter, compared to the consensus estimate of $551.05 million. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 6.38 EPS for the current year.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.